Kornimate/medical-research-clean huggingface dataset:
taking posna's orthokids to the people

Conditions: Fracture Forearm; Pediatric ALL

Summary: the objective of this project is to determine the efficacy of a tablet-based educational intervention at improving orthopaedic health literacy amongst families of pediatric patients treated for fractures in an outpatient setting.

this project aims to reduce knowledge disparity amongst caregivers of patients presenting for pediatric fracture care. at our institution, many patients presenting with fractures do not have easy access to either technology or the internet, preventing caregivers from benefiting from educational tools such as posna's orthokids®. we are planning to increase access and improve health literacy through a simple intervention of providing tablet-based access to posna's orthokids while families are waiting for their physician. families will be randomized to either standard waiting room experience vs. tablet-based educational intervention to limit selection bias. a brief pre-visit questionnaire will be completed by all caregivers to assess fracture and cast care knowledge as well as the highest educational degree obtained by the caregiver.

Eligibility criteria:
inclusion criteria (rct and observational arms): * children with forearm fractures who presented to the chnola ed. "children" are defined as persons under the age of 18 years for this study. "forearm fracture" is defined as a radial and or ulnar shaft fracture for this study. * documented radiographs must show an injury in which the fracture line is wholly located within the diaphysis of the radius or ulna. exclusion criteria (rct and observational arms): * fractures that require internal or external fixation * fractures associated with multi-system trauma * caregivers that do not speak english or spanish as their first language

Keywords: health literacy pediatric fractures orthokids
study comparing two vay736 drug products in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this study will assess the safety and pharmacokinetic comparability of two vay736 drug products in patients with rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * fulfill 2010 acr/eular criteria for ra aletaha et al 2010 at screening * active disease defined as ≥ 2 swollen joints (of 58 evaluable joints) and ≥ 2 tender joints (of 60 evaluable joints) despite stable mtx ≤ 25 mg/week and/or hydroxychloroquine ≤ 400 mg/day treatment for at least 2 months prior to randomization exclusion criteria: * prior or previous use of (specific dosages and intervals prior to study start may apply): other investigational drugs, b-cell depleting therapy (e.g. rituximab), monoclonal antibodies (mab), i.v. / s.c. ig, thymoglobulin, i.v. or oral cyclophosphamide, oral cyclosporine, soluble cytokine receptors, azathioprine. * currently receiving prednisone \>10 mg/day (or equivalent oral glucocorticoid) or dose adjustment within 2 weeks prior to randomization * active viral, bacterial or other infections requiring systemic treatment at the time of screening or enrollment, or history of recurrent clinically significant infection or of bacterial infections with encapsulated organisms * receipt of live/attenuated vaccine within a 2-month period before randomization * pregnant or nursing (lactating) women * women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception from screening and for 4 months after stopping of investigational drug

Keywords: rheumatoid arthritis vay736 ianalumab
interbody fusion devices in the treatment of cervicobrachial syndrome

Conditions: Radiating Pain; Myelopathy; Cervicobrachial Syndrome

Summary: this study randomizes neck and arm pain patients being treated with discectomy and anterior interbody fusion into two groups: one to receive a new ceramic implant and a control group with a more traditional plastic implant. the study will measure and compare pain and disability improvement with the two products over a period of two years. the fusion status will also be judged with plane x-rays and one ct scan.


Eligibility criteria:
inclusion criteria: * age 18 75 years * radicular signs and symptoms in one or both arms (i.e., pain, paraesthesiae or paresis in a specific nerve root distribution) or symptoms and signs of acute or chronic myelopathy. * at least 8 weeks prior conservative treatment (i.e., physical therapy, pain medication) * radiographic diagnosis of cervical disc herniation and/or osteophyte at 1 level (c3-c4 to c7-t1) in accordance with clinical signs and symptoms * ability and willingness to comply with project requirements * written informed consent given by the subject or the subject's legally authorised representative exclusion criteria: * previous cervical surgery (either anterior or posterior) * increased motion on dynamic studies (\> 3 mm) * severe segmental kyphosis of the involved disc level (\> 7 degrees) * patient cannot be imaged with mri * neck pain only (without radicular or medullary symptoms) * infection * metabolic and bone diseases (osteoporosis, severe osteopenia) * neoplasma or trauma of the cervical spine * spinal anomaly (klippel feil, bechterew, opll) * severe mental or psychiatric disorder * inadequate dutch language * planned (e)migration abroad in the year after inclusion

Keywords: cervicobrachial pain radicular pain arm pain myelopathy radiculitis radiating pain with or without signs of myelopathy.
short (5 days) versus long (14 days) duration of antimicrobial therapy for acute bacterial sinusitis in children

Conditions: Sinusitis

Summary: the investigators objective is to compare short course (5 days) to long course (14 days)antibiotics for the treatment of acute bacterial sinusitis in children. the investigators hypothesize that short course therapy will lead to more frequent relapses of sinusitis and will not reduce resistant organisms.

this was a prospective, randomized, double-blind study comparing short course (5 days) to long course (14 days) antimicrobial therapy for children between 1 and 10 years of age with acute bacterial sinusitis. the major outcome measure is the proportion of children with a clinical relapse on day 10 in the short course therapy group compared to day 20 in the long course therapy group. in addition, the proportion of respiratory flora that are resistant to antibiotics on day 30 will be compared to baseline in each group.

Eligibility criteria:
inclusion criteria: 1. children with nasal discharge (of any quality) or daytime cough (which may be worse at night) or both persisting for 10 days or more without evidence of improvement. 2. families need to be english speaking exclusion criteria: 1. used antibiotics within the last 15 days; 2. had symptoms for \> 30 days; 3. have concurrent streptococcal pharyngitis or acute otitis media (as the standard doses for both of these conditions is 10 days); 4. are allergic to penicillin; 5. have symptoms that suggest a complication due to acute bacterial sinusitis that necessitates hospitalization, intravenous antibiotics or sub-specialty evaluation 6. been diagnosed with either immunodeficiency or anatomic abnormality of the upper respiratory tract 7. history of recurrent acute sinusitis (more than 3 episodes in 6 months or 4 episodes in a year) 8. history of chronic sinusitis (more than 90 days of respiratory symptoms in this or the previous respiratory season) 9. girls who have begun menstruating

Keywords: child child, preschool sinusitis antimicrobial agents
double-blind, trial to evaluate the safety and efficacy of mrx-6 cream 2%

Conditions: Atopic Dermatitis

Summary: randomized, double-blind, parallel group, placebo-controlled, multicenter, efficacy and safety study in subjects with mild to moderate atopic dermatitis. following the double blind period, subjects will be allowed to continue treatment with topical mrx-6 cream 2% in an open-label extension. demonstrate the efficacy of mrx-6 cream 2% compared to vehicle for the treatment of the signs and symptoms of atopic dermatitis and demonstrate the safety of mrx-6 cream 2% for the treatment of the signs and symptoms of atopic dermatitis.


Eligibility criteria:
inclusion criteria: * subjects, ≥2 years of age and ≤17 years of age, of any race or ethnicity * must have clinical diagnosis of mild to moderate atopic dermatitis (ad) at both screening and baseline visits, defined as iga score of 2 or 3 (hanifin and rajka, rothe 1980) * must have ad affecting ≥ 5% total body surface area (tbsa) at baseline * history of ad for at least 3 months prior to baseline * informed consent/assent in accordance with the international conference on harmonization (ich) good clinical practice (gcp) guideline (21 cfr §50.25\[c\]) and applicable regulations, before completing any study-related procedures exclusion criteria: * use of topical corticosteroids within 7 days prior to baseline * use of systemic corticosteroids, topical calcineurin inhibitors, photo-therapy (eg, puva, uvb) or immunosuppressive therapy (eg, cyclosporine) within 14 days prior to baseline * subjects that require systemic therapy for the treatment of atopic dermatitis * use of systemic anti-infective or antibiotic treatment within 14 days prior to baseline * subjects who present with clinical conditions other than ad that may interfere with the evaluation (eg, generalized erythroderma, acne, netherton's syndrome, psoriasis) * secondary infection of ad (bacterial, viral or fungal) within the skin area under study or open skin infections in any area at baseline * women of childbearing potential who are lactating or pregnant as determined by urine pregnancy test at screening. • history of mrx-6 cream 2% sensitivity or to any component of the test article * history of severe anxiety and/or depression; any history of suicide attempt * subjects with a history of human immunodeficiency virus (hiv) as determined by medical history * subjects with any screening clinical laboratory result outside the normal range that is clinically relevant in the opinion of an appropriately qualified physician * subjects who, in the opinion of the investigator, would be non compliant with the visit schedule or study procedures * participation in any other investigational trial within 6 weeks of baseline, or during study conduct * chronic condition(s) which are either unstable or not adequately controlled * use of non-sedating anti-histamines within 7 days of first dose or at any time during study conduct * drug or alcohol abuse, mental dysfunction, or other condition limiting the subject's ability to be compliant with study-related procedures
a study to evaluate the safety of an investigational drug (etoricoxib) in patients with osteoarthritis (oa) or rheumatoid arthritis (ra)(0663-066)

Conditions: Rheumatoid Arthritis,Osteoarthritis

Summary: the study is designed to compare the risk of cardiovascular events (heart attacks, strokes) in patients receiving either etoricoxib or diclofenac. it will also compare the gastrointestinal tolerability of the two medicines. the study will be conducted in patients with either rheumatoid or osteo-arthritis.


Eligibility criteria:
inclusion criteria: * patient has a clinical diagnosis of either osteoarthritis or rheumatoid arthritis and in the opinion of the investigator will require chronic nonsteroidal anti-inflammatory or cox-2 inhibitor therapy for at least 1.5 years exclusion criteria: * concurrent medical or arthritic disease that could confound or interfere with efficacy evaluation. * concomitant therapy of warfarin, heparin, high-dose aspirin (\>100 mg/day). * impaired kidney function, clinical gastrointestinal malabsorption, congestive heart failure with symptoms that occur at rest, unstable angina, uncontrolled high blood pressure, active hepatitis/hepatic disease

Keywords: arcoxia
effect of iron and vitamin d supplementation to iron status in iron deficiency anemia

Conditions: Iron Deficiency, Anaemia in Children

Summary: iron and vitamin d are two essential micronutrients for the normal growth of young children, and their deficiencies are still a major health problem in developing countries, including indonesia. a significant association between vitamin d deficiency and anemia has been reported throughout the world. several studies in various populations all over the world suggest a high degree of association between iron deficiency anemia and vitamin d deficiency. it is still controversial which deficiency causes the other but this association should be addressed in view of a better treatment proposal. the aim of the present study was to determine the effect of vitamin d supplementation on iron status in iron deficiency anemia.

this research is a randomized controlled trial study conducted in makassar, south of sulawesi, indonesia from april to october 2023. this study was conducted on children with a diagnosis of iron deficiency anemia. patients were divided into two groups, namely group a which received standard therapy (fe preparations) 3 mg/kgbw/day, and group b (which received standard therapy combination vitamin d, 400iu). the inclusion criteria in this study were children aged 1-5 years, diagnosed with iron deficiency anemia, and parents/caregivers willing to include their children in this study. children who had received iron preparation, and previous blood transfusion were excluded in this study. patients who refused blood tests after giving therapy for 4 weeks were declared dropouts. researchers will provide informed consent to parents/caregivers of children who met the research criteria. anamnesis, general physical examination, and complete blood count (cbc) analysis were carried out: hemoglobin (hb), red blood cell (rbc), mean erythrocyte volume (mcv), mean erythrocyte hemoglobin (mch), reticulocytes, serum iron, and serum ferritin. iron deficiency anemia if the level of hemoglobin \<11 g/dl, microcytic hypochromia, serum ferritin \< 30 pg/dl, then given iron and vitamin d preparation for 4 weeks, then checked again complete blood count, serum fe and serum ferritin. the research results are recorded in a research form and the data is grouped and spss version 21.0 software is used for data analysis. a p value \<0.05 was considered for statistical analysis. this study was approved by the ethics and research committee of the faculty of medicine, at hasanuddin university

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of children's iron deficiency anemia 2. must be able to drink syrups exclusion criteria: 1. patients who have diarrhea 2. patients who experience vomiting 3. severe anemia 4. post transfusion

Keywords: vitamin d iron status iron deficiency anemia
efficacy of changing to travatan® from prior therapy

Conditions: Open-angle Glaucoma; Ocular Hypertension

Summary: the purpose of this study was to assess the efficacy and tolerability of travatan® solution without bak (benzalkonium chloride) after changing from prior latanoprost 0.005% ophthalmic solution monotherapy in subjects with open-angle glaucoma or ocular hypertension due to tolerability issues.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of ocular hypertension or open-angle glaucoma in at least one eye; * on latanoprost ophthalmic solution 0.005% monotherapy (including bak-containing generics) for at least 4 weeks prior to the screening visit, but would benefit from a switch to travatan® bak-free because of tolerability issues, in the opinion of the investigator; * intraocular pressure (iop) \<30 millimeters of mercury (mmhg) in both eyes while on latanoprost ophthalmic solution 0.005% monotherapy; * iop considered to be safe (in the opinion of the investigator), in both eyes, in such a way that assured clinical stability of vision and the optic nerve throughout the study period; * willing to discontinue the use of all other ocular hypotensive medications prior to receiving the study medication for the entire course of the study; * able to follow instructions and willing and able to attend all study visits; * best corrected snellen visual acuity of 6/60 (20/200; 1.0 logmar) or better in each eye; * must sign an informed consent form; * other protocol-defined inclusion criteria may apply. exclusion criteria: * known medical history of allergy, hypersensitivity, or poor tolerance to any component of the preparations to be used in this study deemed clinically significant in the opinion of the principal investigator; * any abnormality preventing reliable applanation tonometry in either eye; * corneal dystrophies in either eye; * concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye; * any clinically significant, serious, or severe medical condition; * use of any systemic medications known to affect iop which have not been on a stable course for at least 7 days prior to the screening visit or an anticipated change in the dosage during the course of the study; * severe dry eye or keratoconjunctivitis sicca which has been or is currently being treated with the use of punctal plugs, punctal cautery, restasis®, or topical ocular corticosteroids; * intraocular conventional surgery or laser surgery in either eye less than 3 months prior to the screening visit; * risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment; * progressive retinal or optic nerve disease from any cause; * women who are pregnant, lactating, or not using reliable means of birth control; * other protocol-defined exclusion criteria may apply.

Keywords: glaucoma open-angle glaucoma ocular hypertension hypertension eye diseases vascular diseases cardiovascular diseases travoprost antihypertensive agents cardiovascular agents therapeutic uses pharmacologic actions
developing computerised cbt for adults with ocd

Conditions: Obsessive-compulsive Disorder

Summary: the study aims to pilot a new computerised cognitive behavioural therapy programme for a small case series of adults with obsessive-compulsive disorder. the investigators hypothesise that the findings will demonstrate improvements in symptomatology following the programme. the programme will have longer-term aims of being rolled out over a number of iapt services within the nhs, reducing waiting lists and increasing therapist time.


Eligibility criteria:
inclusion criteria: * adults aged 18 or over with ocd as defined by dsm-iv who are seeking cbt. * the patient describes their ocd as their main problem and scores between 14 and 30 on the ybocs (goodman et al, 1989). a score above 30 is in the severe range and indicates that the cbt should probably be therapist delivered. * able to use self-help materials in english and answer written questionnaires. * able to access the internet (either at home or in a public library or drop in centre or at the clinic). * have a current episode of ocd of more than 6 months in duration. exclusion criteria: * significant and complex co-morbidity (e.g. significant personality disorder, severe depression or alcohol dependence, which requires longer therapy or is more difficult to treat). such patients are likely to be part of a community mental health team or be funded by the department of health's national specialist commissioning team scheme for severe treatment refectory ocd. * current active suicidal intent or severe self-neglect that requires hospitalisation. * the patient has a primary problem of compulsive hoarding (as such patients are more complex or are more likely to be under a community mental health team). * continuing to receive another form of psychotherapy. * has received cbt for ocd in the past year. * a participant may be taking an anti-depressant for ocd but must be on a stable dose for at least 12 weeks prior to entry in the trial with no plans to alter the dose during the trial period. there must also be no plan to commence on an anti-depressant or anti-psychotic medication. (participants excluded because of their current or planned medication may be offered a further assessment for the trial after being on a stable dose

Keywords: obsessive-compulsive disorder cognitive behavioural therapy computerised
a feasiblity study of green activity program for people living with memory challenges

Conditions: Mild Cognitive Impairment; Alzheimer Disease; Subjective Cognitive Decline (SCD)

Summary: the purpose of this study is to test the green activity program that was designed with people living with memory challenges and their study partners to see if it can be done and if they enjoy the program. "green activities" are nature activities that the person enjoys and can be done with other people or pets. for example, dog walking, hiking, outdoor yoga, and gardening are all green activities. the purpose of the program is to help people living with memory challenges participate in nature activities they enjoy. the goal of the program is to help people stay active and improve their health and well-being.

this is a single arm pre/post feasibility study lasting up to 1 year. investigators will recruit in n=40 dyads (people living with memory challenges and their study partners n=80 total) and expect n=30 (n=60 total people living with memory challenges and study partners) to complete the 12-week gap and evaluate it for feasibility and acceptability. anonymous program evaluation surveys will be administered either via paper or redcap survey to the outdoor activity professionals who participated in the study. brief recorded phone interviews (5 minutes) will be conducted with the people living with memory challenges and their study partners after the intervention and 15-minute brief calls with the outdoor activity professionals will be used to gather feedback to refine the program. informal conversations with the occupational therapist(s) delivering the intervention will occur to identify areas for refinement and will be documented with anonymous notes and no identifiable data collected from them. sustained behavior change will be measured in people living with memory challenges at 4 weeks after the intervention.

Eligibility criteria:
inclusion criteria: * 45 years or older * has memory challenges or difficulties thinking * have access and ability to respond to the telephone (mobile or landline) study partner * 18 years or older * speaks spanish or english * identified by the plmc as a person they feel comfortable with who they would like to join them in the study. the study partner's participation is based on level of support needed for the plmc. outdoor activity professionals * 18 years or older * at least 1 year experience providing outdoor activities exclusion criteria: * participants living with memory challenges will be excluded if they do not meet inclusion criteria or if they indicate any of the following on the 2023 physical activity readiness questionnaire + (par-q+) * heart failure or difficulty controlling coronary artery disease, diagnosed abnormality of heart rhythm, or other cardiovascular condition. * cancer and are actively receiving therapies * experienced a black out, fainted, or lost consciousness as a result of a head injury in the past 12 months. * often experienced signs and symptoms of low blood sugar (hypoglycemia) following exercise and/or daily activities. * \>3 hospitalizations in the past year
nursing care management of external fixation in hospitalization: pin site infection incidence

Conditions: Infection

Summary: the incidence of pin site infection is related to the nursing management of external fixation.


Eligibility criteria:
inclusion criteria: * 18 year old patients exclusion criteria: * immune depression * patients who are treated with immunosupressive drugs or steroids

Keywords: pin site infection after external fixation